



diabetes
research
western
australia

Annual REPORT 2023

Presented at the Annual General Meeting 23 October 2023



The Diabetes Research Foundation of Western Australia
Incorporated (Trading as Diabetes Research WA)

CONTENTS

- 3** Board, Executive & Staff
- 4** Chairman's Report
- 8** Medical Advisory Panel Research Grant Report
- 9** Financial Report
- 15** Auditor's Independence Declaration
- 16** Financial Statements
- 27** Declaration by Members of the Committee
- 28** Independent Audit Report
- 31** Key Supporters

OFFICE

Level 5 Ainslie House
48 Murray Street
PERTH WA 6000

CONTACT

Ph: (08) 9224 1006

info@diabetesresearchwa.com.au
www.diabetesresearchwa.com.au

ABN: 43 743 957 408

Board, Executive & Staff

2022-2023



Office Holders

Chairman	Mr Peter Kerr
Vice Chairman	Dr Joey Kaye
Secretary	Mrs Emily Clarke
Treasurer	Mrs Lana Weldon

Ordinary Board Members

Professor Elizabeth Davis
Ms Josie Fourie
Mr Brad Russell-Lane
Mrs Dorienna Parsons

Manager


Dr Caitlin Fox-Harding

Medical Advisory Panel

Chairman	Dr Joey Kaye
Members	Professor Elizabeth Davis
	Dr Gerard Chew
	Dr Gerry Fegan
	Dr Seng Khee Gan
	Clinical Professor Tim Jones

Auditor

Crunch Auditing



Chairman's Report

2022-2023



I have pleasure in reporting the successful fundraising and research activities for **Diabetes Research WA** (DRWA) during the 2022/23 financial year, during which we continued to pursue our key objectives to:

- investigate the causes and complications of all forms of diabetes;
- search for new ways to prevent and control diabetes; and
- fund research which can contribute to identifying a cure for diabetes.

The volunteer Board and dedicated personnel within the organisation worked hard to raise funds in a competitive environment and to promote the clear benefits to individuals and governments of focused sensible research into diabetes, one of the key diseases faced throughout our modern communities.

Strategy

The Board pursued the existing strategy with DRWA's key vision being a "World without Diabetes" and our purpose being "to fund and advance research for the prevention, control and cure of all forms of diabetes". During the year we worked on key initiatives relating to our fundraising activities, promotion and branding, and partnerships. We also sought to re-structure our organisation to reduce costs and ensure that we continue to allocate the vast majority of our funding directly into critical research projects.

Research Activities

We continued to fund the successful research projects from the last two years and awarded a new \$60,000 research grant for 2023. Numerous worthy local research funding applications were received, with the grant being awarded to Dr Lakshini Herat – who is based at Royal Perth Hospital and the University of Western Australia's School of Biomedical Sciences – for a project entitled "Dual Inhibition of SGLT1 and 2 with Sotagliflozin – a Novel Approach to Maximize Cardiorenal Protection in Type 1 Diabetes". The research project investigates whether a new type of medication used to lower blood glucose levels in those with type 2 diabetes may also help to reduce health complications for those with type 1 diabetes. The drug being studied, sotagliflozin, is one of a relatively new class of oral anti-hyperglycaemic medications which suppress two proteins known as SGLT1 and SGLT2, and researchers believe this medication may provide superior protection to the heart and kidneys, which is critical given that diabetes is a leading cause of end-stage kidney and cardiovascular disease. Initial results appear promising and we look forward to reporting on Dr Herat's work in due course.



We are grateful for the submissions from all grant applicants and in particular for the efforts of the medical and research specialists who offered their valuable time, for no cost, to assess the various grant applications we received.

Other research projects from previous years have also been completed, or are nearing completion, and we look forward to reporting positive outcomes in our regular research updates going forward.

Centre for Diabetes Research

DRWA continues to support the Centre for Diabetes Research (CDR) and Professor Grant Morahan and his team based at the Harry Perkins Research Institute. Significant research outcomes have been achieved over many years and, in particular, DRWA through CDR has committed to support Professor Morahan's involvement in a new Federal Government-sponsored national research centre known as the Australian Centre for Accelerating Diabetes Innovations (ACADI). Through DRWA, CDR has committed up to \$250,000 for the validation and extension of a genetic test that identifies those living with type 1 diabetes who are at high risk of developing diabetic kidney disease, the objective being to facilitate timely treatment and better health outcomes for those that might otherwise suffer serious diabetes-related complications.

Support and Fundraising Activities

Key fundraising activities during the year included generous donations from companies and individuals, as well as our new DRWA "weekend away" fundraising raffle, which was successfully completed and will form part of our future fundraising events. DRWA was also the grateful recipient of bequests totalling approximately \$365,000 which will be utilised to fund future research programs in the pursuit of DRWA's longer term objectives. Since the end of the financial year, a number of new bequests have been received or notified to us, totalling in excess of \$200,000.

Our inaugural Jamie "Crippa" Cripps kids' footy clinic was a tremendous success, with around 50 kids with type 1 diabetes attending a footy clinic and BBQ hosted by Jamie Cripps of the West Coast Eagles, along with various of his AFL and AFLW colleagues. The tour through the West Coast Eagles training facilities was a highlight. We are grateful to Jamie for his role as a key ambassador for DRWA and we look forward to the next Crippa Clinic in December 2023.

DRWA is also the beneficiary of generous donations in terms of time and financial support from various suppliers, supporters and sponsors. Similar with previous years, these include Adam Donkin and Mark Smith of Two Moons Consulting, as well as Elfin Database Solutions and our various Ambassadors and advocates, being our sports ambassador Jamie Cripps, our film ambassador Jenni Baird, our long-standing legacy ambassador John Lewis and our art ambassador Norah Murphy. Thanks also to Natalie Caudle of Capture Media for her professional assistance with our written and on-line media presence. We are also grateful for support from our volunteers and recognise Royal Perth Hospital which provides our office space.



Collaborations

During the year we also pursued our strategy for collaborations with other diabetes-related organisations. In particular, we engaged with the senior Australian leadership team of JDRF and provided preliminary assistance with the formation of its Global Centre of Excellence based at the Telethon Kids Institute and Perth Children's Hospital. We look forward to further collaboration with JDRF and other diabetes-related institutions in due course, for the benefit of all individuals with diabetes.

Thank you

As members would be aware, in April 2023 and after 26 years of dedicated service, Sherl Westlund retired from the organisation to pursue her own personal consulting activities. We are tremendously grateful to Sherl who has been instrumental in the growth and success of DRWA over an amazing period of service. This sentiment was thoroughly supported by all those volunteers and supporters who attended Sherl's goodbye function. We acknowledge and thank her for her commitment and efforts. It is a wonderful achievement.

Since Sherl's departure, we are very fortunate to have secured the services of Caitlin Fox-Harding as our new DRWA Manager. Many of our supporters have already met Caitlin, who with a very thorough handover from Sherl, has quickly grasped our key activities and will work actively with the Board in driving DRWA's research successes.

It is through the efforts of our small team and key suppliers and advisors, along with support from each of our Board members, volunteers, researchers, supporters and donors, that DRWA's long standing success and future sustainability is ensured.

We look forward to the coming year with a keen focus on our diabetes research projects and continuing our fundraising capacity to achieve our broader research objectives.

Peter Kerr
Chairman
Diabetes Research WA

Research Report 2022-2023



For 2023 and 2024, DRWA made a strategic decision to only award one grant. Applications from both basic science research and clinical translational areas were considered with independent peer review of all grant applications undertaken. The Medical Advisory Panel remains especially grateful to all the reviewers who voluntarily gave up their time to assist with the review process. Their expertise ensures the application and assessment process conforms to the highest standards of scientific rigor and administrative transparency.



The 2023 DRWA research grant was awarded to Dr Lakshini Herat from UWA School of Biomedical Sciences and Dobney Hypertension Centre for her project entitled: **Dual Inhibition of SGLT1 and 2 with Sotagliflozin – a Novel Approach to Maximize Cardiorenal Protection in Type 1 Diabetes.** This study will investigate the role of sodium-glucose transporter (SGLT) proteins in the development and potential prevention or treatment of diabetic retinopathy and builds on previous work by Dr Herat and her affiliated team that demonstrated a role for one particular protein (SGLT 2) in a mouse model of retinopathy. Inhibitors of the SGLT 2 protein are commonly used in the treatment of diabetes with established additional kidney and heart benefits. During their earlier studies, they identified that mice with diabetes had an increased production of a related form of this transport protein (SGLT 1). This study now aims to examine the role this particular version has in diabetic retinopathy.

Dr Joey Kaye
Chairman
DRWA Medical Advisory Panel



diabetes
research
western
australia

Annual FINANCIAL REPORT

For the year ended 30 June 2023



Annual Financial Report

For the year ended 30 June 2023



Statement of Financial Position as at 30 June 2020

TABLE OF CONTENTS

COMMITTEE REPORT	11
AUDITOR'S INDEPENDENCE DECLARATION	16
FINANCIAL STATEMENTS	17
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	18
STATEMENT OF FINANCIAL POSITION	19
STATEMENT OF CASH FLOWS	20
STATEMENT OF CHANGES IN ACCUMULATED FUNDS	21
NOTES TO THE FINANCIAL STATEMENTS	22
1. GENERAL INFORMATION AND STATEMENT OF COMPLIANCE	22
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	22
3. REVENUE	25
4. EXPENSES	25
5. CASH AND CASH EQUIVALENTS	25
6. TRADE AND OTHER RECEIVABLES	25
7. OTHER ASSETS	25
8. EQUIPMENT	26
9. TRADE AND OTHER PAYABLES	26
10. EMPLOYEE BENEFITS	26
11. EVENTS AFTER THE BALANCE SHEET DATE	27
12. RELATED PARTY TRANSACTIONS	27
13. COMMITMENTS	27
14. CONTINGENT LIABILITY	27
15. THE CENTRE FOR DIABETES RESEARCH (INC.)	27
DECLARATION BY MEMBERS OF THE COMMITTEE	28
INDEPENDENT AUDIT REPORT	29

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT For the year ended 30 June 2023

COMMITTEE REPORT

The Members of the Committee present their Report together with the financial report of The Diabetes Research Foundation of Western Australia (Inc.) trading as “Diabetes Research WA” (“the Association” or “DRFWA”) for the year ended 30 June 2023 and the auditor’s report thereon.

COMMITTEE MEMBERS OF THE ASSOCIATION

Mr Peter Kerr

Office Holder - Chairperson

Peter is an Australian Chartered Accountant with more than 25 years’ experience in the mining industry in Australia and Canada, including corporate, operations and senior executive roles. He is presently Chief Executive Officer at Mount Gibson Iron Limited. Having been part of DRFWA’s Committee from 1997 to 2000 and greatly admiring the work of the organisation over a long period, Peter returned to Australia and later re-joined DRFWA in October 2015. Peter was appointed Chairperson in May 2017 and is passionate about research into all forms of diabetes.

Dr Joey Kaye

Office Holder – Deputy Chairperson

Joey is a Consultant Endocrinologist and the Director of Diabetes Services at Sir Charles Gairdner Hospital in Western Australia. Joey completed his undergraduate medical training at The University of Western Australia, physician training at various hospitals in Western Australia and completed specialist training in Endocrinology and Diabetes in 2001. Joey undertook a PhD in neuro-endocrinology at the University of Bristol in the UK from 2000-03. Joey joined the DRFWA Committee in 2006.

Ms Emily Clarke

Office Holder - Secretary

Emily leads the Alternative Legal Services’ Disputes practice in Australia for Herbert Smith Freehills. Emily commenced with the firm in 2005 and was promoted to Senior Associate in 2015. Emily leads an experienced team of qualified lawyers, legal analysts and eDiscovery specialists based across Brisbane, Melbourne, Perth and Sydney. Emily joined the DRFWA Committee in November 2020.

Dr Lana Weldon

Office Holder - Treasurer

Lana is a highly experienced Chartered Accountant and non-executive director and is currently the General Manager and National Head of Quality Management for Moore Australia. Lana relocated to Perth from South Africa at the beginning of 2020. She previously spent over 20 years in accounting education as an Association Professor at the University of Fort Hare, whilst consulting in accounting and governance. She joined the DRFWA Committee in October 2020 as Honorary Treasurer.

Professor Elizabeth Davis

Ordinary Committee Member

Professor Liz Davis is an Australian clinical researcher in paediatric diabetes. She received paediatric endocrinology training in Perth and at the University of Pennsylvania and received her PhD from the University of Western Australia. Professor Davis is the Head of the Department of Endocrinology and Diabetes at Perth Children’s Hospital. She co-directs the Rio Tinto Children’s Diabetes Centre at the Telethon Kids Institute, an integrated Clinical and Research centre. Liz joined the DRFWA Committee in 2006.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT For the year ended 30 June 2023

COMMITTEE REPORT - continued

Ms Josie Fourie

Ordinary Committee Member

Josie has 25 years of corporate experience in the resources sector, predominantly in the fields of engineering and operations management. In addition to this technical background, Josie has experience in a range of business areas such as management systems, contracts, strategy, policy development and assurance processes. She is accountable for managing substantial budgets and risks and is passionate about corporate responsibility and values-based leadership. In 2016, Josie completed the foundational program at the Centre for Ethical Leadership in Melbourne. Josie joined DRWA in October 2020.

Mr Brad Russell-Lane

Ordinary Committee Member

Brad is the former Chief Executive Officer of the North West Shelf Gas Project and Vice President Australia Business at Woodside Energy where he worked from 1989 until his retirement in 2018. Brad is a Corporate and Business Advisor to various organisations, particularly in the indigenous business area, and a coach and mentor to young and emerging CEOs in the resource sector. Brad was diagnosed with type 1 diabetes at the age of 36 and is an advocate for workplace and corporate giving, believing that diabetes research in Western Australia is world-class. Brad joined the DRFWA Committee in 2017.

EXECUTIVE MANAGEMENT

Ms Sherl Westlund

Executive Director (resigned 7 April 2023)

Sherl joined DRFWA in 1997 and has over 30 years' experience in the not-for-profit (NFP) sector. Sherl ensured DRFWA continued to focus on funding world-class research into diabetes in Western Australia by collaborating and partnering with institutions, organisations, community and individuals. She recognises the vital role research plays in changing the future and the impact quality research has for those living with or at risk of diabetes and the associated complications. Sherl's contribution to the NFP sector was recognised in 2019 by The Australian Institute of Management WA when she became a Fellow of the Institute. Sherl concluded her time with DRWA in April 2023 following 26 years of dedicated service.

Dr Caitlin Fox-Harding **Manager**

Caitlin commenced working for DRWA in June 2023. Dr Fox-Harding holds a PhD from The University of Sydney in Exercise and Sports Science (2019) and has since been an academic/researcher at Edith Cowan University in Exercise Medicine and Sport/Exercise Psychology. Outside of academia, Caitlin has been involved in various governance, administration and high-performance management capacities for the Olympic sport of fencing in Australia as well as the international governing body, the Fédération Internationale d'Escrime (FIE).

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT For the year ended 30 June 2023

COMMITTEE REPORT - continued

MEETINGS OF MEMBERS OF THE COMMITTEE

The number of meetings of the Association's Committee held during the year ended 30 June 2023, and the number of meetings attended by each member of the Committee, were:

Members of the Committee	Committee Meetings	
	A	B
Ms Emily Clarke	4	3
Professor Elizabeth Davis	4	3
Ms Josie Fourie	4	2
Mr Peter Kerr	4	4
Dr Joey Kaye	4	2
Mr Brad Russell-Lane	4	4
Dr Lana Weldon	4	3
Ms Sherl Westlund (resigned April 2023)	3	3
Dr Caitlin Fox-Harding (appointed June 2023)	1	1

A = Number of meetings eligible to attend

B = Number of meetings attended

PRINCIPAL ACTIVITY

The principal activity of the Association during the year was to act as a charitable institution providing research funds to Western Australian diabetes researchers. No significant change in the nature of this activity occurred during the year.

DIVIDENDS

As the Association has no share capital, no dividends are payable.

REVIEW OF OPERATIONS

DRFWA is a private charitable Association dedicated to the funding of research in Western Australia focused on the prevention, control and cure of all types of diabetes. The Association's objectives are to fund the State's best researchers to investigate the causes and complications of all forms of diabetes, to search for new ways to prevent and control diabetes, and to discover a cure for diabetes. Funds are sourced from bequests, fundraising initiatives including specific events and crowdfunding, workplace and corporate giving, and generous personal and corporate donations.

KEY STRATEGIES FOR ACHIEVING OBJECTIVES

Through the Association's efforts, funds are sourced for the purpose of enabling world-class diabetes research in Western Australia. The Association awarded an annual research grant in 2022/23 to an applicant through a formal and competitive application process. The selection of grant awardees each year is overseen by an independent Medical Advisory Panel. This panel reviews all grant applications and makes recommendations to the Members of the Committee on the worthiness of such applications. Approval of research grants is ultimately decided by the Committee.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT For the year ended 30 June 2023

COMMITTEE REPORT - continued

MEASUREMENT OF PERFORMANCE

The success of DRFWA is measured through formal and informal monitoring of its key objectives for each year. The Committee meets approximately every two months and at each meeting reviews the financial, marketing and research outcomes of the Association, and its future plans. The key areas monitored include:

- Compliance with regulatory and acceptable business practices;
- Effective management of the Association;
- Cost control;
- Periodic fundraising targets;
- Applications and processes for the assessment and award of research grants;
- Website “hits” and enquiries, and media presence; and
- Performance of fundraising and other programs against expectations.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

During the year, the Association continued to raise funds from general estate bequests and donations from members and other individuals and companies, and to apply these funds to diabetes research projects and general running costs. Various initiatives were pursued to reduce operating costs and, with the assistance of the Executive Director, improve the efficiency and effectiveness of the Association.

Other than as noted above, there were no significant changes in the state of affairs during the financial year.

MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR

No other matters or circumstances have arisen since 30 June 2023 that have significantly affected the Association’s operations, results or state of affairs, or may do so in future years.

ENVIRONMENTAL REGULATION

The Association’s operations are not subject to any significant environmental regulations under either Commonwealth or State Legislation.

INDEMNIFICATION AND INSURANCE OF OFFICERS AND AUDITORS

Since the start of this financial year, the Association has not indemnified or made a relevant agreement for indemnifying against a liability for any person who is or has been an officer or auditor of the Association.

During the financial year the Association has paid premiums in respect of Members of the Committee and Officers’ liability and legal expenses insurance contracts for the year ending 30 June 2023. Such insurance contracts insure against liability (subject to specific exclusions) arising against persons who are or have been Members of the Committee or Officers of the Association.

COMMITTEE MEMBERS’ BENEFITS

During the year no member of the Committee has received or become entitled to receive any benefit by reason of a contract made by the Association with the member of the Committee or with a firm of which he or she is a member or a company in which he or she has a substantial financial interest, except as otherwise disclosed in Note 12 of the financial statements.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT For the year ended 30 June 2023

COMMITTEE REPORT - continued

RESEARCH PROJECT GRANTS PAID

In the 2022-23 financial year, the Association paid cash grants (excluding GST) totalling \$120,000 (2021/22: \$90,000) as listed below:

	2022-23	2021-22
	\$	\$
University of Western Australia – K Pflieger	30,000	30,000
University of Western Australia – A Filipovska		60,000
University of Western Australia – M Abraham	30,000	
University of Western Australia – G Dwivedi	30,000	
University of Western Australia – L Herat	30,000	
	<u>120,000</u>	<u>90,000</u>

To ensure that the Association is kept updated and across any issues with the research, DRFWA typically releases half of the funds for each research project upon receipt of an invoice and the remainder mid-way through the research project following receipt of a suitable interim report.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the Auditor's Independence Declaration as required under section 60.40 of the Australian Charities and Not-for-profits Commission Act 2012 (ACNC) is set out on the following page and forms part of this Committee Report.

This Committee Report is made in accordance with a resolution of the Members of the Committee.



Peter Kerr
Chairperson



Lana Weldon
Treasurer

Perth
26 September 2023

**The Diabetes Research Foundation of Western Australia (Inc.)
ANNUAL REPORT
For the year ended 30 June 2023**

AUDITOR'S INDEPENDENCE DECLARATION

To the Committee of The Diabetes Research Foundation of Western Australia Inc:

As lead engagement partner for the audit of The Diabetes Research Foundation of Western Australia Inc for the year ended 30 June 2023, I declare that, to the best of my knowledge and belief, there have been:

- No contraventions of the independence requirements in relation to the audit; and
- No contraventions of any applicable code of professional conduct in relation to the audit.

Michael Cooper

Crunch Auditing

26 September 2023

**The Diabetes Research Foundation of Western Australia (Inc.)
ANNUAL REPORT
For the year ended 30 June 2023**

FINANCIAL STATEMENTS

This financial report covers The Diabetes Research Foundation of Western Australia (Inc.), trading as “Diabetes Research WA” (the “**Association**” or “**DRFWA**”), as an individual entity.

The financial report is presented in Australian currency.

DRFWA is a not-for-profit association incorporated in Western Australia under the Associations Incorporation Act (WA) 2015. Its registered office and principal place of business is:

Level 5 Ainslie House
RPH Precinct
48 Murray Street
Perth WA 6000

A description of the nature of the Association’s operations and its principal activities is included in the Committee Report on pages 10–14, which does not form part of these financial statements.

The financial statements were authorised for issue by the Members of the Committee on 26 September 2023.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 June 2023

		<i>Year Ended 30 June</i>	<i>Year Ended 30 June</i>
	<i>Notes</i>	2023	2022
		\$	\$
Revenue from continuing operations	3	413,868	74,368
Expenses			
Employee benefits expenses		(115,956)	(164,187)
Advertising and promotion		(42,447)	(47,234)
Other expenses	4	(29,877)	(19,782)
Research grants expensed during the year		(120,000)	(90,000)
Surplus/(deficit) for the year		105,588	(246,835)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT

STATEMENT OF FINANCIAL POSITION AS AT 30 June 2023

	<i>Notes</i>	30 June 2023 \$	30 June 2022 \$
ASSETS			
Current assets			
Cash and cash equivalents	5	404,200	331,773
Trade and other receivables	6	3,687	6,983
Other assets	7	2,245	3,142
Total current assets		410,132	341,898
Non-current assets			
Equipment	8	3	435
Total non-current assets		3	435
TOTAL ASSETS		410,135	342,333
LIABILITIES			
Current liabilities			
Trade and other payables	9	13,085	15,074
Employee benefits	10	164	35,961
Total current liabilities		13,249	51,035
TOTAL LIABILITIES		13,249	51,035
NET ASSETS		396,886	291,298
ACCUMULATED FUNDS			
Retained Earnings		396,886	291,298
TOTAL ACCUMULATED FUNDS		396,886	291,298

The above statement of financial position should be read in conjunction with the accompanying notes.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 June 2023

	<i>Notes</i>	30 June 2023	30 June 2022
		\$	\$
Cash flows from operating activities			
Donations received		47,193	58,281
Bequests received from deceased estates		365,638	-
Interest received		617	32
Memberships		420	684
Other income		-	15,371
Payments to suppliers and employees		(221,441)	(230,109)
Research and education payments		(120,000)	(90,000)
Net cash flows from/(used in) operating activities		72,427	(245,741)
Cash flows used in investing activities			
Acquisition of office equipment		-	-
Net cash flows used in investing activities		-	-
Net increase/(decrease) in cash and cash equivalents		72,427	(245,741)
Cash and cash equivalents at beginning of period		331,773	577,514
Cash and cash equivalents at end of period	5	404,200	331,773

The above statement of cash flows should be read in conjunction with the accompanying notes.

The Diabetes Research Foundation of Western Australia (Inc.) ANNUAL REPORT

STATEMENT OF CHANGES IN ACCUMULATED FUNDS FOR THE YEAR ENDED 30 June 2023

	Accumulated Funds \$
Balance at 1 July 2021	538,133
Deficit for the year	<u>(246,835)</u>
Balance at 30 June 2022	<u>291,298</u>
Balance at 1 July 2022	291,298
Surplus for the year	<u>105,588</u>
Balance at 30 June 2023	<u><u>396,886</u></u>

The above statement of changes in accumulated funds should be read in conjunction with the accompanying notes.

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023

1. GENERAL INFORMATION AND STATEMENT OF COMPLIANCE

This financial report includes the financial statements and notes of The Diabetes Research Foundation of Western Australia (Inc.) (the “**Association**”).

These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards – Simplified Disclosure. The Association is a not-for-profit entity for the purpose of preparing the financial statements.

The financial statements for the year ended 30 June 2023 were approved and authorised for issue by the Members of the Committee on 26 September 2023.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies that have been used in the preparation of these financial statements are summarised below.

The financial statements have been prepared using the measurement bases specified by Australian Accounting Standards for each type of asset, liability, income and expense. The measurement bases are more fully described in the accounting policies below.

2.1 Basis of Preparation

Historical cost convention

These financial statements have been prepared on a going concern basis and under the historical cost convention.

Critical accounting estimates

Preparation of financial statements in conformity with Australian Accounting Standards requires the use of certain critical accounting estimates. It also requires management to exercise judgement in the process of applying the Association’s accounting policies. There were no areas involving higher degrees of judgement or complexity, or areas where assumptions and estimates were significant to the financial statements of the Association.

Functional and presentation currency

Items included in the financial statements of the Association’s operations are measured using the currency of the primary economic environment in which the entity operates (“functional currency”). The financial statements are presented in Australian dollars, which is the Association’s functional and presentation currency.

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023 (continued)

2.2 Revenue Recognition

Revenue is measured by reference to the fair value of consideration received or receivable, when the Association is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations

Donations are recognised when the amounts are received. In common with most organisations dependent on such contributions, the Association is unable to establish control over voluntary donations prior to their initial entry into the accounting records.

Bequests

Revenue is recognised when bequests are received by the Association.

Interest Revenue

Interest Revenue is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.

2.3 Property, Plant and Equipment

Property, plant and equipment is stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by the Association.

Where a bequest is received in the form of assets, these are recognised at fair value at the date acquired.

Depreciation is recognised on a straight-line basis to write down the cost less estimated residual value of the asset. The estimated useful lives range as follows:

IT Equipment	3 to 5 years
Furniture, fittings and other equipment	3 to 8 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognised in profit or loss within other income or other expenses.

2.4 Income Tax

The Diabetes Research Foundation of Western Australia (Inc.) is exempt from tax under Subdivision 50-B of the Income Tax Assessment Act 1997.

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023 (continued)

2.5 Cash and Cash Equivalents

Cash and cash equivalents include cash at bank and other short term highly liquid investments with original maturities of three months or less.

For the purposes of presentation in the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above. Cash flows are presented in the Statement of Cash Flows on a gross basis.

2.6 Payables

These amounts represent liabilities for goods and services provided to the Association prior to the end of the financial year which are still outstanding. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value.

2.7 Employee benefits

The liability for employee benefits relates to amounts expected to be paid to employees for annual leave, long service leave, salary sacrifice and superannuation. It is based on legal and contractual entitlements. Current wage rates are used in the calculation of the provision.

2.8 Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST components of investing and financing activities, which are disclosed as operating cash flows.

2.9 Contingent Liabilities

Where there exists a possible obligation, defined as having a less than a 50% chance of becoming a present obligation, the Association recognises a contingent liability.

2.10 Adoption of new and revised accounting standards

The Association has adopted all standards which become effective for the first time at 30 June 2023. The adoption of these standards has not caused any material adjustments to the reported financial position, performance or cash flow of the Association.

2.11 New accounting standards and interpretations

The Australian Accounting Standards Board has issued new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods. The Association has decided not to early adopt these Standards.

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023 (continued)

	30 June 2023 \$	30 June 2022 \$
3. REVENUE		
General donations	47,193	56,182
Bequests from deceased estates	365,638	2,099
Memberships	420	684
Interest	617	32
Other Income	-	15,371
	413,868	74,368
4. EXPENSES		
Other Expenses		
Audit fees	1,600	2,100
Insurance	6,945	5,883
Depreciation	429	1,149
Other administration costs	20,903	10,650
	29,877	19,782
5. CASH AND CASH EQUIVALENTS		
For the purposes of the Cash Flow Statement, cash and cash equivalents comprise the following at 30 June:		
Cheque accounts (including funds awaiting term deposits)	404,200	331,773
6. TRADE AND OTHER RECEIVABLES		
Net GST receivable	3,687	6,983
7. OTHER ASSETS		
Prepayments - Insurance	2,245	3,142

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023 (continued)

8. EQUIPMENT

Gross carrying amount	Furniture and Fixtures	IT Equipment	Total
Balance 1 July 2022	619	5,464	6,083
Balance 30 June 2023	619	5,464	6,083

Accumulated Depreciation	Furniture and Fixtures	IT Equipment	Total
Balance 1 July 2022	526	5,122	5,648
Depreciation charge	92	340	432
Balance 30 June 2023	618	5,462	6,080

Carrying Amount	Furniture and Fixtures	IT Equipment	Total
At 1 July 2022	93	342	435
At 30 June 2023	1	2	3

9. TRADE AND OTHER PAYABLES

	<i>30 June</i> 2023	<i>30 June</i> 2022
	\$	\$
Accrued expenses	4,527	4,981
PAYG withholding payable	8,073	6,156
Superannuation payable	485	3,937
	<u>13,085</u>	<u>15,074</u>

10. EMPLOYEE BENEFITS

Liability for leave	<u>164</u>	<u>35,961</u>
---------------------	------------	---------------

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2023 (continued)

11. EVENTS AFTER THE BALANCE SHEET DATE

No adjusting or significant non-adjusting events have occurred between the reporting date and the date of authorisation.

12. RELATED PARTY TRANSACTIONS

The Association's related parties include its Key Management Personnel as described below.

Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

Transactions with Key Management Personnel

Key management of the Association are the Members of the Committee, the Manager and the former Executive Director. Details of these individuals are disclosed in the Committee Report. Other than the Manager and former Executive Director who received remuneration, the other Members of the Committee of DRFWA did not receive any emoluments during the year. No Members of the Committee are associated with companies or firms which provided paid services to the Association during the year.

13. COMMITMENTS

The Association has the following diabetes research commitments as at 30 June 2023:

- Remaining amount of \$30,000 for the research grant 'Oral insulin therapy on glycaemic responses with type 1 diabetes' - Dr Mary Abraham from Perth Children's Hospital and the Telethon Kids Institute.
- Remaining amount of \$30,000 for the research grant 'Dual Inhibition of SGLT1 and 2 with Sotagliflozin – a Novel Approach to Maximize Cardiorenal Protection in Type 1 Diabetes – Lakshini Herat from RPH Research Foundation at the UWA School of Biomedical Sciences and Dobney Hypertension Centre.

14. CONTINGENT LIABILITY

There are no contingent liabilities that have been incurred by the Association in relation to the financial year ended 30 June 2023.

15. THE CENTRE FOR DIABETES RESEARCH (INC.)

In 1998, the Diabetes Research Foundation of Western Australia (Inc.) agreed to provide the Centre for Diabetes Research (Inc.) with funds of \$400,000 to commence the organisation. There was no obligation for the Centre to repay these funds. During the 2022 financial year, the Centre returned \$240,000 to the Foundation. The current cash balance held by the Centre is \$ 254,777.

DECLARATION BY MEMBERS OF THE COMMITTEE

In the opinion of the Members of the Committee of The Diabetes Research Foundation of Western Australia (Inc.):

The financial statements and notes of The Diabetes Research Foundation of Western Australia (Inc.) are in accordance with the Australian Charities and Not-for-profits Commission Act 2012, including:

- i. Giving a true and fair view of its financial position as at 30 June 2023 and of its performance for the financial year ended on that date; and
- ii. Complying with Australian Accounting Standards – Simplified Disclosure (including the Australian Accounting Interpretations).

There are reasonable grounds to believe that The Diabetes Research Foundation of Western Australia (Inc.) will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Members of the Committee.



Chairman – Mr Peter Kerr



Treasurer – Dr Lana Weldon

Dated: 26 September 2023

Independent Audit Report to the members of The Diabetes Research Foundation of Western Australia Inc

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of The Diabetes Research Foundation of Western Australia Inc (the Entity), which comprises the statement of financial position as at 30 June 2023, the statement of profit and loss and comprehensive income, the statement of changes in accumulated funds and the statement of cash flows for the year then ended, notes to the financial statements and the declaration by members of the committee.

In our opinion, the accompanying financial report presents fairly, in all material respects, including:

- (i) giving a true and fair view of the Entity's financial position as at 30 June 2023 and of its financial performance and its cash flows for the year ended; and
- (ii) complying with Australian Accounting Standards – Simplified Disclosure.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Entity in accordance with the auditor independence requirements of the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance

Management is responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of the financial report is free from material misstatement, whether due to fraud or error.

In preparing the financial report, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.



Crunch Auditing Pty Ltd
enquiry@crunchauditing.com.au
www.crunchauditing.com.au
ABN: 43 158 633 615

Crunch Auditing Pty Ltd

Crunch Auditing Pty Ltd



Michael Cooper
04 October 2023



Crunch Auditing Pty Ltd
enquiry@crunchauditing.com.au
www.crunchauditing.com.au
ABN: 43 158 633 615

Our Key Donors, Researchers and other Supporters during the 2022/2023 Financial Year

The corporate and community support we receive at Diabetes Research WA is critical to our success. This comprises donations, memberships, sponsorship, professional services, discounted rates for services and products we need, volunteering, fundraising and helping us find a cure for diabetes.

Dr Mary Abraham
Mr Allan Ashby
Mr Muhammad Awais
Mr John Baines
Ms Jenni Baird
Mrs Eileen Beecroft
Mr Richard Berg
Mrs P Butler
Leigh and Jenna Cameron
Capture Media/Ms Natalie Caudle
Trina Cattalini
Caversham Primary School
Dr Gerard Chew
Mr Anderson Clarke
Ms Emily Clarke
Mrs Emma Cobby
Mrs Dione Coleman
Mr & Mrs J Coleman
Mr William Coleman AM
Mr Jamie Cripps & Family
Professor Elizabeth Davis
Angela Del Caro
Dinner Twist
DRWA Medical Advisory Panel
DRWA Research Grant Assessors
Mr Adam Donkin
Mr Richard Dougal
Professor Girish Dwivedi
Ms Bronwyn Edmonds
Elfin Database Solutions
Joan & Wayne Endersby
Mr Alwyn Even
Dr Gerry Fegan
Mrs Maureen Felton
Professor Alexandra Filipovska
Ms Angela Formato
Ms Josie Fourie
Claudia Gadomsky
Dr Seng Khee Gan
Mr Stephen Gardner
Mr Ian Garrett
Mr John Gaunt
Ms Sally Gaunt
Ms Jessica Gavin
Mr Robert (Bob) George
Goldclass Detailing
Mr Albert Gough
Mr Lloyd Guthrey
Harry Frederick Carter Charitable Trust
Ms Renate Haubner

Dr Aveni Haynes
Dr Lakshini Herat
Mrs Kate Hiatt
Gregory Frank Hunt
Ms Pru Holland
Mrs Janet Holmes a Court AC, AO
IGA East Victoria Park
Miss Janey Ip
Sarah Jemerson
Mrs Lesley Johnson
Mr Geoffrey Jones
Clinical Professor Tim Jones
Professor Yogesan Kanagasingam
Dr Joey Kaye
Ms Shannon Keay
Mr Bob Kerr
Mr Peter Kerr
Leanne Knowler
Mr & Mrs John & Wendy Kusmierek
Ms Janette Lano
Dr Christine Lawson-Smith
Mr John Lewis
Lindentech
Amanda Lindley
Lions Club of North Beach
Mrs Kim Siew Loo
Mr Ashton Lush
Ms Liz McGrath
Mr Richard McKenna
Associate Professor Julia Marley
Professor Barry and Mrs Adrienne Marshall
Mrs Margaret Martin
Dr Vance Matthews
Ms Kate Maxwell
Ms Miranda Miller
Mineral Resources Limited
Mrs Nancy Mills
Mrs Louise Mioceovich
Ms Krysta Mitchell
Ms Rebekah Montgomery
Mrs Isabella (Belle) Moore
Professor Grant Morahan
Ms Haylee Moyle
Miss Norah Murphy
Mr Robert O'Connor QC
Professor Fergal O'Gara
Ms Kristy O'Neill
Mr Colin Pearse
Carola Penman
Professor Kevin Pflieger

Stan Perron Charitable Foundation
Linlee Pontifix
Ms Emma Ratcliffe
Mrs Marion Reid
Haden Reynolds
Royal Perth Hospital
Mr Brad Russell-Lane
Mr & Mrs E Russell-Lane
Paul Scaffidi
Professor Marcus Schlaich
Burley Sekem
Ms Chloe Shaw
Mr Paul Sherlock
Mrs Linda Shipster
Shoreline 4x4
Ms Chris Simons
Mr Matt and Mrs Beth Smith
Mr Mark Smith
Ms Erica Smyth AC
Leo Sokol
Sarah Soon
Dr Gary Stein
Ms Jennie Stevens
Mr Malcolm Teale
Telethon Kids Institute
Telethon Speech & Hearing Centre
Mr Brian Thompson
Mr G W Thompson
Mr Kevin Trent
Two Moons Consulting
United Way
Mrs Kerry Vincenti
Dr Lana Weldon
Mrs Norma West
West Coast Eagles Football Club
Ms Sherl Westlund
Ms Sarah Wheeler
Ms Marjeanne Wilkins
John Arthur Wilkes
Ms Christine Wooldridge
Ms Kate Wilson
Woodside Energy Ltd
Lucia Wright

And all other supporters who prefer not to be acknowledged or who may have been accidentally missed.

Diabetes Research WA Team, Board, Executive & Staff

Office Holders

Chairman: Mr Peter Kerr
Vice Chairman: Dr Joey Kaye
Secretary: Ms Emily Clarke
Treasurer: Ms Lana Weldon

Ordinary Board Members

Professor Elizabeth Davis
Ms Josie Fourie
Mr Brad Russell-Lane
Mrs Doriena Parsons

Manager

Dr Caitlin Fox-Harding

Medical Advisory Panel

Chairman Dr Joey Kaye
Professor Elizabeth Davis
Dr Gerard Chew
Dr Gerry Fegan
Dr Seng Khee Gan
Clinical Professor Tim Jones

Auditor

Crunch Auditing PTY Ltd



diabetes research
western australia

'RESEARCH IS THE KEY TO OUR FUTURE'

Diabetes Research WA would like to thank all those who have supported our endeavours and who by their generosity allow research into the causes, complications and an ultimate cure for diabetes to continue. We are deeply appreciative and look forward to informing you of any breakthroughs as they come to hand. Diabetes Research WA relies on funding from non-government sources. We ask that you continue to support us in our research. For more information please visit our website.

Level 5, Ainslie House, RPH Precinct
48 Murray Street, Perth WA 6000
PO Box X2213 Perth WA 6847

T: +61 8 9224 1006

E: info@diabetesresearchwa.com.au
diabetesresearchwa.com.au